▎ 摘　　要

NOVELTY - Nanocomplex comprises graphene oxide (GO) and cationic silver moieties bound to the GO. USE - The nanocomplex is useful in composition for providing antimicrobial effect and treating microbial infection by killing microbial pathogens chosen from Gram-positive bacterium, Gram-negative bacterium, fungus, virus, antimicrobial resistant strain, and multidrug resistant (MDR) strain. The virus is a non-enveloped virus or an enveloped virus. The enveloped virus is coronavirus, preferably severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The microbial pathogen is (a) chosen from Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter baumannii, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Staphylococcus aureus, Candida auris, and influenza virus, or (b) chosen from P.aeruginosa, E.coli, K.pneumoniae, S.marcescens, A.baumannii, S.maltophilia, S.pneumoniae, S.aureus, C.auris, influenza virus, extended spectrum beta lactamase (ESBL) E.coli, ESBL K.pneumoniae, carbapenem-resistant organisms (CRO) Enterobacter spp., penicillin-resistant S.pneumoniae, community-associated methicillin-resistant S.aureus (MRSA) infections (CA-MRSA), hospital-acquired (HA)-MRSA, and A.baumannii complex, preferably E.faecium, S.aureus, K.pneumoniae, A.baumannii, P.aeruginosa, and Enterobacter sp. (ESKAPE) pathogen. The microbial infection is bacterial infection, viral infection, fungal infection, respiratory tract infection, or multidrug resistant infection. The multidrug resistant infection is bacterial infection, viral infection, fungal infection or respiratory tract infection. The viral infection is an influenza virus infection. The fungal infection is a C.auris infection. The respiratory tract infection is (i) bacterial infection, where the bacterial infection is Corynebacterium diphtheriae, Neisseria gonorrhoeae, Mycoplasma pneumoniae, M.hominis, Haemophilus influenzae, S.pneumoniae, M.pneumoniae, S.aureus, S.pyogenes, K.pneumoniae, E.coli, P.aeruginosa, Legionella spp., Mycobacterium tuberculosis, Coxiella burnetii, Chlamydia pneumoniae infection, (ii) a viral infection, where the viral infection is an influenza virus, flavivirus, parainfluenza virus, respiratory syncytial virus, coronavirus, adenovirus or rhinovirus infection, or (iii) a fungal infection, where the fungal infection is a C.albicans, Aspergillus spp., Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis, or Coccidioides immitis infection. The respiratory tract infection is rhinitis, sinusitis, pharyngitis, epiglottitis, laryngitis, bronchitis, bronchiolitis, or pneumonia (all claimed). The subject includes human and non-human animals such as mammals, birds and fish, and encompasses domestic, farm, zoo, laboratory and wild animals such as cows, pigs, horses, goats, sheep or other hoofed animals, dogs, cats, chickens, ducks, non-human primates, guinea pigs, rabbits, ferrets, rats, hamsters and mice. ADVANTAGE - The nanocomplex avoids recurrent microbial infections, is stable in water without the need for additional chemicals, solvents or post-processing, and minimizes systemic adverse effects. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) antimicrobial formulation comprising the above-mentioned nanocomplex, and a solvent, a carrier, a diluent, and/or a dispersant; (2) composition comprising the nanocomplex; and (3) kit comprising a container comprising the above-mentioned composition, where the container is adapted to deliver the composition by an intranasal or pulmonary route.